Real-world treatment drop-off among recurrent or metastatic cervical cancer patients: A US community oncology-based analysis
Author:
Funder
Seagen Inc
Seagen
Publisher
Elsevier BV
Subject
Obstetrics and Gynecology,Oncology
Reference33 articles.
1. Cancer statistics, 2022;Siegel;CA Cancer J. Clin.,2022
2. Follow-up for women after treatment for cervical cancer: a systematic review;Elit;Gynecol. Oncol.,2009
3. Phase II trial of nab-paclitaxel in the treatment of recurrent or persistent advanced cervix cancer: A gynecologic oncology group study;Alberts;Gynecol. Oncol.,2012
4. Management of patients with recurrent/advanced cervical cancer beyond first line platinum regimens: where do we stand? A literature review;Boussios;Crit. Rev. Oncol. Hematol.,2016
5. Phase II clinical trial of docetaxel in refractory squamous cell carcinoma of the cervix: a gynecologic oncology group study;Garcia;Am. J. Clin. Oncol.,2007
Cited by 7 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study;Journal of Clinical Oncology;2023-12-20
2. Assessing Geographic Variation in Rates of Cervical Cancer and Recurrent or Metastatic Cervical Cancer Among Medicaid Enrollees;American Journal of Clinical Oncology;2023-07-17
3. Patterns of care and health care resource use among Medicaid-enrolled women with recurrent or metastatic cervical cancer;Journal of Managed Care & Specialty Pharmacy;2023-05
4. Previous radiation patients may not be a good candidate to consider the adding bevacizumab for rescue therapy;Taiwanese Journal of Obstetrics and Gynecology;2023-01
5. WITHDRAWN: Factors associated with receipt of second-line recurrent or metastatic cervical cancer treatment in the United States: A retrospective administrative claims analysis;Gynecologic Oncology Reports;2022-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3